Check this box Section 16. For

obligations may Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
m 4 or Form 5	
continue. See	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kirby John J.					<u>ID</u>	2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDRA]									ionship of Reportir all applicable) Director Officer (give title		10% Othe	Owner (specify	
(Last)					3. D	3. Date of Earliest Transaction (Month/Day/Year)								Λ	belov	,	belov ncial Officer	v)	
C/O IDERA PHARMACEUTICALS, INC.			01/	01/07/2020															
505 EAGLEVIEW BLVD., SUITE 212				4 15												- Fili (Ob l	A		
(Stroot)					- 4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
EXTON	(Street) EXTON PA 19341												X Form filed by One Reporting Person						
					-									Form filed by More than One Reporting Person					
(City)	(St	ate) (Zip)																
		Tabl	e I - N	on-Deriv	ative	Secu	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefici	ally	Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)						Execution Date,		ate,	3. 4. Securitie Transaction Code (Instr. 8)					and 5) Secu Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			(111341. 4)	
Common Stock 01/07/2					020			S		911(1)	D	\$1.78	04(2) 1		6,437 ⁽³⁾	D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Executic if any (Month/IDay/Year) (Month/IDay/Year)					5. Null of Deriving Securing Acquing (A) or Disposof (D) (Instruand 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			vative (9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Date		Expiration		Amount or Number of						

Explanation of Responses:

- 1. Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,562 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- 2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$1.76 to \$1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. Of the reported shares, 7,688 shares are represented by unvested RSUs.

/s/ John J. Kirby 01/10/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.